Vishal Jajoo, Senior Equity Research Analyst at Nirmal Bang Securities told CNBC-TV18, "If investors are ready to see some short-term volatility one can continue to remain invested in Sun Pharmaceutical Industries because apart from the recent news that the US Congress is taking certain steps against Indian companies, in addition to that fact Sun Pharma is planning a massive qualified institutional placement (QIP) programme and this programme is to the tune of about minimum Rs 20000-30000 crore and this could be for the acquisition purpose. So that could have certain amount of pressure on the stock and we have already seen certain investigations taking place in the company’s facility at Halol in Gujarat."
"The outcome is still awaited to certain extent but these could be certain set of negative announcements which may have a negative impact in the short-term. But overall the outlook continues to be bullish over the long-term. It has been one of the biggest wealth creators in the pharma space and since the outlook is for a pretty long horizon, I would advise to remain invested," he added.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
